US02043Q1076
US02043Q1076
Alnylam Pharmaceuticals, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 31.13B EUR | 40.26B EUR | 44.15B EUR | 52.64B EUR |
Enterprise Value | 29.72B EUR | 39.82B EUR | 43.71B EUR | 52.26B EUR |
Valuation Multiples | ||||
Trailing P/E | 39.24x | 49.82x | 77.29x | 144.11x |
Forward P/E | 18.73x | -- | -- | -- |
Price to Sales | 6.48x | 8.38x | 10.3x | 16.87x |
Price to Book | 22.98x | 29.73x | 41.06x | 66.7x |
EV/Revenue | 6.19x | 8.29x | 10.2x | 16.75x |
EV/EBITDA | 28.19x | 34.69x | 48.14x | 86.59x |
Price to FCF (P/FCF) | 114.66x | 49.1x | 68.63x | 88.52x |
EV/FCF | 109.46x | 48.57x | 67.95x | 87.88x |
FCF Yield | 0.87% | 2.04% | 1.46% | 1.13% |